TSE:4523 - Eisai Co., Ltd.

General

TSE:4523

11/20/2024

Muscle atrophy side custody agent "Rose Baramine® Muscle Note 25mg", newly released in Japan

TSE:4523

11/20/2024

Anti -cancer agent "Tasfigo® Tablets 35mg" (General name: Tasl Gratinibcohacute) In Japan, newly released with the effects and effects of biliary tract cancer with FGFR2 fusion gene.

TSE:4523

11/15/2024

Started broadcasting a TV commercial for the purpose of enlightenment of MCI (mild cognitive impairment) nationwide -my daughter is always worried that "I said it a while ago."

TSE:4523

11/15/2024

Received an approval recommendation from the European Pharmaceutical Committee (CHMP), the early Alzheimer's disease treatment agent

TSE:4523

11/5/2024

Azai Group's Corporate Venture Capital EISAI Innovation, Inc. adopted the AMED "drug discovery venture ecosystem reinforcement project"

TSE:4523

11/1/2024

Completed a gradual application for a biological formulation approval application for the US FDA regarding the maintenance and administration of the subcutaneous injection formulation of the early Alzheimer's disease treatment agent

TSE:4523

10/31/2024

Announced data on benefits by continuous treatment of Recanemab with dual action at the 17th Alzheimer's Disease Clinical Clinical Test Conference (CTAD) - The new measurement method reveals the relationship between Protofibrilill and neuromotatory biomar

TSE:4523

10/31/2024

Anti -MTBR (microtubo -binding area) The latest clinical data that suggests the suppression of tau propagation by administration of the tau antibody E2814 is announced at the 17th Alzheimer's disease Clinical trial meeting - isolation early Alzheimer's di

TSE:4523

10/30/2024

About the sales revenue (breaking news) of the anti -amyloid β -protector antibody "Rekenbi®"

TSE:4523

10/24/2024

At the 17th Alzheimer's disease clinical trial meeting (CTAD), the latest data of Recanemab with dual action, research on blood biomarkers that predicts the accumulation of amyloid in the brain, and the latest data on anti -MTBR (microtum binding area) ta

TSE:4523

10/17/2024

The evaluation of the amyloid β accumulation prediction in the brain by the Shimadzu Seisakusho, Eisai, Oita University, Usuki City Medical Association, a co -hortin research blood biomarker

TSE:4523

10/17/2024

About the approval status of Recanemab as an early Alzheimer's disease treatment in Australia

TSE:4523

10/16/2024

Vial shading and packaging for the "Rose Baramin® Muscle Note" is awarded the Good Design Award in the 2024 in 2024 Good Design Award

TSE:4523

10/8/2024

Gout and hyperuricemia treatment agents "URECE® Tablets" (general name: Dochinulado), acquired approval in Thailand

TSE:4523

10/4/2024

Notice regarding the acquisition status of self -stock and the end of acquisition

TSE:4523

10/2/2024

Saudi pharmaceutical sales subsidiaries have started business activities

TSE:4523

10/1/2024

Notice regarding the acquisition status of self -stock — acquisition of self -stocks based on the provisions of the Articles of Incorporation under the provisions of Article 459, Paragraph 1 of the Companies Act -

TSE:4523

9/26/2024

Eisai Co., Ltd. personnel changes and organizational reorganization

TSE:4523

9/24/2024

For "25mg for Rose Baramine® Muscle Note" (general name: Mekobaramine), acquired manufacturing and sales approval in Japan as a contract for muscle atrophy lateral sclerosis.

TSE:4523

9/24/2024

Anti -cancer agent "Tasfigo® Tablets 35mg" (General name: Tasl Gratinibcohacute) Acquired manufacturing and sale approval in Japan with FGFR2 fusion genes

TSE:4523

9/17/2024

"World Alzheimer's Month" Dementia Diseases Awareness Enlightenment Videos of Public Dementia Six months of documentary "Today, Tomorrow" - I know, so I can be kind.

TSE:4523

9/17/2024

Combined therapy that adds a liver aortic chemical embolism (TACE) to "Renbima®" (Renbachinib) and "Kitruda®" (Pemblolismab) compared to TACE independent therapy, in non -remote non -metasty hepatocellular cell carcinoma., Significant survival period (cli

TSE:4523

9/12/2024

Check the tumor-decomposed inducing drug E7820 with J-PDX (Japanese cancer patient-based tissue transplant model) and launch a doctor's initiative-established a drug discovery research system that accelerates the development of new anticancer drugs.Aiming

TSE:4523

9/5/2024

Announcement of products and developments in Eisai's cancer area at the European Society of Clinical Tumor (ESMO)

TSE:4523

9/2/2024

TSE:4523

8/27/2024

Obvious videos of insomnia for the falling sleep health week

TSE:4523

8/22/2024

In the "Rekubi®" (Recanemab) and the UK (excluding the Northern Ireland), the approval of the early Alzheimer's disease -the adaptation of Recanemab is a mild cognitive recognition of Alzheimer's disease in adults whose APOE ε4 is a heterocyclic or non -h

TSE:4523

8/14/2024

"Leqembi®" obtained approval as Alzheimer's disease treatment in the United Arab Emirates

TSE:4523

8/6/2024

About the development application status of subcutaneous inserts for anti -amyloid β protector antibody "Rekenbi®"

TSE:4523

8/1/2024

TSE:4523

8/1/2024

About the sales revenue (breaking news) of the anti -amyloid β -protector antibody "Rekenbi®"

TSE:4523

7/31/2024

New clinical data shows that three -year continuous treatment by "Rekenbi" with dual action will continue to provide remarkable benefits to early Alzheimer's disease party at Alzheimer's Disease Association International Conference (AAIC) 2024 — in the br

TSE:4523

7/26/2024

About the approval status of Recanemab in the EU

TSE:4523

7/24/2024

Aisai and Eco Nava have started concluding and collaboration with a business alliance contract to build a dementia ecosystem

TSE:4523

7/23/2024

At the Alzheimer's Disease Association International Conference 2024 (AAIC2024), the effectiveness and safety data of Recanemab, which has dual action, is announced, discussing long -term outcomes due to continuous treatment — Progressive and continues af

TSE:4523

7/16/2024

Concluded a license agreement in Asia and Oceania in Hoslab Konazole with Sato Pharmaceutical

TSE:4523

7/12/2024

"Rekenbi®" (Recanemab) obtained approval as Alzheimer's disease treatment in Israel

TSE:4523

7/11/2024

Selected for the second consecutive year of the social responsibility investment index "FTSE4GOOD INDEX Series"

TSE:4523

7/11/2024

"LEQEMBI®" (Recanemab) obtained approval as Alzheimer's disease treatment in Hong Kong

TSE:4523

7/1/2024

Regarding the antibody drug complex Farletuzumab Ecteribulin (FZEC), the transition to Global Development and Commercialization in Eisai alone - ends the strategic partnership with Bristol Myers Squave -

TSE:4523

7/1/2024

TSE:4523

6/28/2024

Eisai Co., Ltd. personnel transfer (July 1, 2024)

TSE:4523

6/28/2024

Alzheimer's disease treatment agent "Rekubi®" (Rechanab) New release in China --Leave the third country in the world following the United States and Japan -

TSE:4523

6/27/2024

About the way of thinking and policies regarding the reduction of investment units

TSE:4523

6/21/2024

Continuing contract with the 2024 dementia screening business in Bunkyo -ku, Tokyo - In 2023, achievement of performance indicators in a private consignment contract method

TSE:4523

6/17/2024

Eisai Co., Ltd. Personnel changes and organizational reorganization (June 14, 2024)

TSE:4523

6/14/2024

Eisai Corporation Executive system

TSE:4523

6/10/2024

A partially changed application of the biological preparation approval approval for the maintenance maintenance and administration of the early Alzheimer's disease treatment agent

TSE:4523

6/3/2024

Selected by TIME magazine "Time100 Most Influental Companies"

TSE:4523

6/3/2024

TSE:4523

6/3/2024

Enhanced venture investment business to accelerate drug discovery innovation and ecosystem platform construction

TSE:4523

5/27/2024

"Leqembi®" (Recanemab) obtained approval as Alzheimer's disease treatment in Korea

TSE:4523

5/23/2024

Announcement of products and developments in Eisai's cancer area at the US Society of Clinical Tumor Society

TSE:4523

5/22/2024

"Methogect® Subcutaneous Pen" (General name: Methotrexate) Newly released pen -type automatic injection device in Japan

TSE:4523

5/15/2024

Notice of matters related to acquiring self -stocks and the cancellation of self -stock — acquisition of self -stocks based on the provisions of the Articles of Incorporation pursuant to Article 459, Paragraph 1 of the Companies Act, and self -stock based

TSE:4523

5/15/2024

Notice regarding the appointment of directors and executive candidates

TSE:4523

5/15/2024

Notice regarding the transfer of representative executive officers

TSE:4523

5/15/2024

Started with a fast track designation of a biological formulation application application for the US FDA regarding the maintenance and administration of subcutaneous injection preparations for the early Alzheimer's disease treatment agent

TSE:4523

5/13/2024

Anti -epileptic agent "Ficonpa®", approved by the adaptation of combined therapy for epilepsy's genuine aggression in China

TSE:4523

4/24/2024

About the sales revenue (breaking news) of the anti -amyloid β -protector antibody "Rekenbi®"

TSE:4523

4/17/2024

About "Research on treatments based on the mechanism of the pathological mechanism of the pathological mechanism of Alzheimer's disease" Awarded the Minister of Education, Culture, Sports, Science and Technology Award (Research Division)

TSE:4523

4/17/2024

Anti -epilepsy agent "Ficonpa®", newly released injections in Japan -response to the needs of patients who cannot take medicine due to oral.

TSE:4523

4/11/2024

Support for damage caused by the eastern Taiwan earthquake

TSE:4523

4/2/2024

French sales subsidiaries, EISAI S.A.S., transferred the rights of "LOXAPAC®" and "Parkinane® LP" to CNX THERAPEUTICS in France

TSE:4523

4/1/2024

Completed an application for a partial change in biological preparation approval to the US FDA for the maintenance and administration of "Rekenbi®" for early Alzheimer's disease treatment

TSE:4523

3/29/2024

Transfer the rights of "Merislon®" and "Myonar®" in Japan to Kaken Pharmaceutical

TSE:4523

3/28/2024

Eisai Co., Ltd. Personnel changes and organizational reorganization (April 1, 2024)

TSE:4523

3/28/2024

The brain health self-check tool "No Know®" is certified as "ME-BYO BRAND" in Kanagawa Prefecture

TSE:4523

3/28/2024

Dual orxin receptor antagonist Remborexant's "2024 Japanese Pharmaceutical Society of Pharmaceuticals"

TSE:4523

3/25/2024

About the reconciliation of patent infringement lawsuits regarding renewable in the United States

TSE:4523

3/22/2024

Anti -amyloid β -protector antibody "Recanemab" has been delayed in Europe Pharmaceuticals Committee (CHMP) due to procedures in the European Pharmaceutical Pharmaceuticals (EMA).

TSE:4523

3/21/2024

Lifenet Life and Eisai jointly developed the dementia insurance "Be" - Support early detection and early treatment of dementia and mild cognitive impairment (MCI).

TSE:4523

3/21/2024

As a listed company that is excellent in promoting women's activities, it is selected as "Nadeshiko brand" in fifth year

TSE:4523

3/6/2024

Invested in C2N Diagnostics LLC to support the simplification of early Alzheimer's disease diagnosis

TSE:4523

2/29/2024

At the 18th Alzheimer Parkinson Society (AD/PD ™ 2024), the latest research results on Alzheimer's disease, including Recanemab, were presented

TSE:4523

2/21/2024

2050 Enhancing initiatives to reduce greenhouse gases to achieve the net zero — Participation in JCI Race to Zero Circle and acquiring approval of SBT1.5 ° C goals —

TSE:4523

2/20/2024

Selected as "Human Capital Leaders 2023" and "Human Capital Management Quality Gold" as a company that works on excellent human capital management and information disclosure

TSE:4523

2/15/2024

"Methogect® Subcutaneous Pen" (General name: Methotrexate) Acquisition of pen -type automatic injection device injection in Japan

TSE:4523

2/1/2024

South Africa's pharmaceutical sales subsidiaries have started business activities -starting their own business in Africa, also established branches in Kenya -

TSE:4523

1/26/2024

Regarding the high -dose preparation of Mecobaramine, applying for a new drug approval in Japan with the adaptation of the muscle atrophy lateral sclerosis (ALS)

TSE:4523

1/18/2024

Anti -epileptic agent "Fimpa®", acquiring injection agents in Japan -response to medical needs for treatment based on oral administration -

TSE:4523

1/17/2024

The eighth selection of "100 Sustainable Company in the World" — ranks the highest in global pharmaceutical companies

TSE:4523

1/16/2024

Announced the latest development research on multiple cancers in ASCO GI and ASCO GU

TSE:4523

1/11/2024

Held the Neuroscal Advisory Group (SAG) on the application for approval in Europe in the anti -amyloid β protector antibody "Recanemab"

TSE:4523

1/9/2024

"Rekenbi®" (Rechanab) acquired approval as Alzheimer's disease treatment -the third country in the world following the United States and Japan -

TSE:4523

1/9/2024

Eisai Co., Ltd. Personnel changes and organizational reorganization (January 9, 2024)

TSE:4523

1/5/2024

Legal 6 years about the support of the Noni Peninsula earthquake

TSE:4523

12/26/2023

Development of amyloid beta accumulation model in the brain using wristband type biological sensors

TSE:4523

12/18/2023

Anti -cancer agent Tasle glatinib, applying for a new drug approval with adaptation related to biliary tract cancer having FGFR2 fusion gene in Japan

TSE:4523

12/13/2023

Eisai and Mizuho Bank concluded a contract for "Sustainability Link Loan"

TSE:4523

12/13/2023

"Rikenbi® Infusion Illusion" (General name: Recanemab) Newly released on December 20 as Alzheimer's disease treatment in Japan

TSE:4523

12/9/2023

Clinical III LEAP-001 test status for primary treatment for combination therapy between "Renbima®" (Renbachinib) and "Kitaruda®" (Pemblolismab) or recurrent endometrial cancer.

TSE:4523

11/30/2023

Agreement in Thailand in collaboration in the Thai Ministry of Health and the dementia area

TSE:4523

11/22/2023

The latest data on Perran Panel is announced at the 77th Annual Meeting of Eye Eye

TSE:4523

11/20/2023

"Rekenbi®" won "Best New Drug" and "CLINICAL ADVANCE OF THE YEAR" in the 19th Scrip Awards.

TSE:4523

11/16/2023

In the 30th anniversary of the Japan IR Council's establishment, selected as "IR IR improved company Premium" and "IR Continuing Company Premium"

TSE:4523

10/26/2023

Announcements of subcutaneous administration of "Regenbi®" and additional analysis of Clarity AD tests are announced at the 16th Alzheimer's Clinical Examination Meeting (CTAD)The subcutaneous administration preparation under development removes 14 % more

TSE:4523

10/25/2023

"Rekenbi®" (Recanemab) is elected to the TIME magazine "THE BEST INVENTINTIONS OF 2023"

TSE:4523

10/17/2023

Eisai Co., Ltd. Personnel changes and organizational reorganization (October 16, 2023)

TSE:4523

10/16/2023

At the 16th Alzheimer's disease clinical trial meeting (CTAD), publish the latest data in the Alzheimer's disease area, including new data from the clinical Clinse of "Rekenbi", and announces the latest information on subcutaneous inserts in "Renbi"-

TSE:4523

10/11/2023

Announcement of products and developments in Eisai's cancer field at the Annual Meeting of the European Clinical Tumor

TSE:4523

10/4/2023

Notice regarding the merger of absorption (simplified merger) of Kang Research Institute Co., Ltd.

TSE:4523

9/28/2023

Eisai Co., Ltd. Personnel changes and organizational reorganization (October 1, 2023)

TSE:4523

9/28/2023

News of the Eisai Corporate website "Innovation" page newly established

TSE:4523

9/28/2023

[In the industry's first] Tokio Marine & Nichido and Eisai jointly developed "dementia treatment support insurance"

TSE:4523

9/25/2023

Acquisition of manufacturing and sales approval as Alzheimer's disease treatment in Japan for "Rekenbi® Infusion Intravenous Intravenous Intra

TSE:4523

9/22/2023

About the status of two clinical phases for metastatic non -small cell lung cancer related to combined therapy of "Renbima®" (Renbachinib) and "Kitroba®" (Pemblolismab)

TSE:4523

9/21/2023

Today on "World Alzhehyeimerday", I released a videos of dementia disease awareness "2023" "Two Memories, One Sokurata Hen" - I know it.

TSE:4523

9/12/2023

Established the digital business company "THEORIA Technologies Co., Ltd." for the construction of dementia ecosystem

TSE:4523

8/25/2023

Clinical Phase II LEAP-010 for recurrence or metastatic head and neck squamous endothelial cancer for combined therapy between "Renbima®" (Renbachinib) and "Kitruda®" (Pemblolismab).

TSE:4523

8/4/2023

Selected as a brand of the social responsibility investment index "FTSE4GOOD INDEX Series" for 22 years

TSE:4523

8/1/2023

Eisai Corporation Personal Transition and Organizational Reorganization (August 1, 2023)

TSE:4523

7/20/2023

Regarding "Recane Mab", the latest analysis results on the pathology of Alzheimer's disease and subcutaneous administration are announced at the Alzheimer's Council International Conference 2023 (AAIC2023) — by detailed analysis of the clinical Phase II,

TSE:4523

7/12/2023

At the Alzheimer's Disease Association International Conference 2023 (AAIC2023), the latest data on the development of Alzheimer's disease / dementia area including anti -Aβ protector antibody Recanemab and anti -MTBR tau antibody E2814

TSE:4523

7/11/2023

Eisai Co., Ltd. personnel transfer (executive personnel transfer on July 10, 2023)

TSE:4523

7/7/2023

"Leqembi®" (Recenemab), as Alzheimer's disease treatment, it has been fully approved from US FDA - suppressing the progress of Alzheimer's disease, and it has been confirmed that cognitive function and decline in daily life function are confirmed, and ful

TSE:4523

6/30/2023

Transfer the rights of all economic revenue of Elacestrant to Dri Healthcare

TSE:4523

6/29/2023

About the way of thinking and policies regarding the reduction of investment units

TSE:4523

6/29/2023

Eisai, GATES Ventures, Health Data Research UK, LifeArc, and the University of Edinburgh launched "Neurii" to develop digital solutions that contribute to solving dementia.

TSE:4523

6/22/2023

Continuing to measure brain health by our "Nou Know®" in the 2023 dementia screening business in Bunkyo -ku, Tokyo - In 2022, achieve the results indicators in a private consignment agreement system.

TSE:4523

6/21/2023

Eisai Co., Ltd. Personnel changes and organizational reorganization (June 21, 2023)

TSE:4523

6/10/2023

The U.S. FDA Advisory Committee unanimously supports the clinical benefits of the Alzheimer's disease treatment "LEQEMBI®" — FDA peripheral / Central Nursing Drug Advisory Committee A large -scale global clinical clinic for early Alzheimer's diseasePhase

TSE:4523

6/8/2023

Apply for new drug approval in Korea for early Alzheimer's disease in South Korea for anti -amyloid β -protector antibody

TSE:4523

6/6/2023

About the occurrence of ransomware damage

TSE:4523

6/2/2023

The latest data of Remborexant is announced at the 37th American Sleeping Association Annual Meeting

TSE:4523

5/26/2023

The combination therapy of "Renbima®" (Renbiachinib) and "Kitaruda®" (Pemblolismab) shows sustainable survival recently as a primary treatment of advanced renal cell cancer for sneakinibs., Clinical Phase II CLEAR (307) Exam/Keynote-581 Examination, after

TSE:4523

5/25/2023

Efforts to develop unauthorized tropical diseases and new drug development of malaria and fund contribution to the third phase of the Global Health Technology Promotion Fund

TSE:4523

5/24/2023

Announcement of products and developments in Eisai's cancer area at the US Society of Clinical Tumor Society

TSE:4523

5/22/2023

For anti -amyloid β -protector antibody "Recanemab", submit a sales approval application for early Alzheimer's disease in the UK (excluding Northern Ireland)

TSE:4523

5/17/2023

Published in the Neurology and Therapy magazine, which specializes in the social value of "Rechanemab" in Japan, using the clinical phase Clarity AD test data

TSE:4523

5/16/2023

Anti -Aamiloid β Protofibrilill antibody "Recanemab" is accepted by the Ministry of Health of Health for new drugs related to early Alzheimer's disease.

TSE:4523

5/15/2023

Notice regarding self -stock disposal by third -party allocation due to the change of the share reward system (executive compensation BIP trust)

TSE:4523

5/15/2023

Notice regarding the change and additional contribution of the reward system for directors and executive officers and the stock reward system (executive compensation BIP trust)

TSE:4523

5/9/2023

Notice regarding correction of achievement forecast (IFRS), 2023

TSE:4523

5/8/2023

Concluded a joint development agreement with BLISSBIO for strategic tie-ups for antibody drug complex BB-1701

TSE:4523

4/7/2023

Regarding the status of clinical Phase II for advanced melanoma (Leap-003) and metastatic colorectal cancer (Leap-017), related to combination therapy of "Renbima®" (Renbachinib) and "Kitaruda®" (Pemblolismab).

TSE:4523

4/6/2023

A large -scale renovation work of the Tsukuba Research Institute is completed - to the Global Drugs Center in Eisai, where people, people, people, data, and people are connected to the world —

TSE:4523

4/4/2023

Clinical Phase II Public Clarity AD The long -term health outcomes of "Recanemab" using the test data are evaluation results using simulation in Neurology and Therapy Magazine Neurology and Therapy.If you start treatment with Rechanemab earlier than to de

TSE:4523

4/3/2023

Regarding anticancer agent Tasemetstat, concluded a contract on cooperation in physician -led clinical research based on the "patient application for medical treatment" system with the National Cancer Research Center

TSE:4523

3/31/2023

New analysis results on ARIA expression and QOL in the Clarity AD test of "Recanemab" were announced at the 17th Alzheimer Parkinson Society (AD/PD ™ 2023)

TSE:4523

3/31/2023

Antiamiloid β (Aβ) Protofibrilill antibody "Recane Mab" is published in an additional analysis for clinical Phase II in the 2010 Examination in the 3 reports in the magazine specializing in rating.

TSE:4523

3/30/2023

Eisai Co., Ltd. Personnel changes and organizational reorganization (April 1, 2023)

TSE:4523

3/24/2023

Annual Meeting on Women's Cancer announces the subject of clinical research in the on -cology field

TSE:4523

3/23/2023

At the 17th Alzheimer Parkinson Society (AD/PD ™ 2023), the latest information on the research on Alzheimer's disease, such as the safety profile, clinical results, and the evaluation of QOL, was presented to Lecane Mab's early Alzheimer's disease.In the

TSE:4523

3/20/2023

Published in the clinical phase Clearity AD, published in the social value of "Recanemab" using the test data in NEUROLOLOGY and THERAPY.

TSE:4523

3/14/2023

For the early Alzheimer's disease treatment "LEQEMBI ™" (Lekneemab), the US Get Person Health Bureau will start covering insurance in two months from the FDA -prompt approval -will be able to contribute to the U.S. veterans for early Alzheimer's disease.,

TSE:4523

3/10/2023

2023 J-Win Diver City Awards "Basic Achievement Award"

TSE:4523

3/9/2023

Certified from 2023 -White 500-

TSE:4523

3/6/2023

"Leqembi ™" (Recanemab), Alzheimer's disease treatment for full approval (SBLA) application for full approval (SBLA) was accepted by US FDA and specified for priority screening — Fda is clinical III AD verification test.The data is evaluated, and the chan

TSE:4523

3/2/2023

Regarding the joint promotion of multiple sclerosis treatment agents in Japan in Japan and Eisai

TSE:4523

2/28/2023

A biological license application (BLA) of the anti -amyloid β protector antibody "Recanemab" is designated as a priority examination

TSE:4523

2/20/2023

About the joint venture of Bracco Eisai

TSE:4523

1/30/2023

Antiamiroid β Protofiblel antibody "Recanemab" is designated as a priority examination item in Japan

TSE:4523

1/27/2023

Regarding the anti -amyloid β -protector antibody "Recanemab", the European Pharmaceutical Pharmaceutical Agency is accepted by the European Pharmaceutical Agency for early Alzheimer's disease.

TSE:4523

1/19/2023

Israeli pharmaceutical sales subsidiaries have started business activities

TSE:4523

1/18/2023

The 7th selection for the "100 Sustainable Company in the World" — ranks the highest in global pharmaceutical companies

TSE:4523

1/18/2023

Announced the latest development research on therapeutic drugs for gastrointestinal cancer at the American Society of Clinical Tumor Society Cancer Cancer 2023

TSE:4523

1/16/2023

Applying for new drug approval in Japan for early Alzheimer's disease in Japan, for anti -amyloid β protector antibody "Recane Mab"

TSE:4523

1/13/2023

Announcement of Eisai Sustainability Page renewal

TSE:4523

1/11/2023

Submit an application approval application for anti -amyloid β -protector antibody "Recanemab" with early Alzheimer's disease.

TSE:4523

1/7/2023

Leqembi ™, submitted a partial change in biological formulation approval (SBLA) for full approval (SBLA) in the United States — based on the data of the Clinical Phase II Clarity AD verification test, On the same day, submit an application for full approv

TSE:4523

1/7/2023

Commitment to the scientific evidence of Eisai and the safety of patients

TSE:4523

1/7/2023

Early Alzheimer's disease treatment LEQEMBI ™ (Recenemab) is an approach of price setting in the United States based on Eisai's concepts on the relationship between "social value of pharmaceuticals" and "price" — Maximizing the value of all stakeholders a

TSE:4523

1/7/2023

Leqembi ™ (Recenemab) obtained rapid approval from the US FDA as a treatment for Alzheimer's disease — quick approval is a clinical phase II test for early AD for early AD that shows a decrease in amyloid β plaque in the brain by leqembi ™ administration.

*Press releases are taken from the company websites.
*Titles may be translated independently.
*Please be aware that, since data is collected automatically, there is a possibility of omissions occurring.

Dividend Amount Graph

Frequency : 2 times / Year

Price-Yield Graph

* The latest yield is calculated by taking the total from the dividend data for the number of times the dividend frequency is used.
If there is still insufficient dividend data for the expected dividend frequency in the current year, calculations are made by going back to past data.
Please report it to us if the information is incorrect.